Protalix BioTherapeutics Inc.
PLX
Get informed when a big investor buys or sells
+ FollowMarket Cap$191.76M
Close$
$-2.48
203.3% downside
Current Fair Value
203.3% downsideOvervalued by 203.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $191.76 Million |
|---|---|
| Enterprise Value | $173.55 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.08 |
| Beta | 0.01 |
| Outstanding Shares | 79,986,325 |
Return
| Return on Equity | 26.53% |
|---|---|
| Return on Assets | 17.17% |
| Return on Invested Capital | 24.25% |
Valuation & Multiples
| P/E Ratio | 9.88 |
|---|---|
| PEG | 0.45 |
| Price to Sales | 2.4 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.15 |
| Enterprise Value to EBIT | 9.06 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$0.27
Average shareholder expectationRevenue Estimate
$37.80 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$13.37 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5186▼ 110.49% |
|---|---|
| Total Calls | 260,500▲ 1432.35% |
| Total Puts | 135,100▲ 389.49% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 21.12%▲ 2.14% |
|---|---|
| Total Invested | $36.57M▲ 36.30% |
| Investors Holding | 106▲ 22.00% |
ESG Score
No data
About Protalix BioTherapeutics Inc.
CEO: Dror Bashan